Follow on Google News News By Tag * Preclinical Research * Strategic Partnership * Formulation * Toxicology * Drug Development * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Calvert Labs and Particle Sciences Partner to Streamline Early-Stage Drug DevelopmentFor over 40 years, Calvert Labs has been partnering with industry leading consultants and Biopharma companies to help them develop the next generation of therapeutics aimed at improving and extending human life. From early-stage lead identification and optimization services to comprehensive GLP IND enabling packages, Calvert Labs offers a wide array of preclinical services. Calvert Labs’ President and Chief Scientific Officer, Charles B. Spainhour, V.M.D, Ph.D., who works closely with clients to develop and implement their preclinical programs, recognizes the value this partnership provides both current and future clients. “Formulation is often one of the most significant challenges our clients’ face. The sooner we can resolve any issues, the more quickly we can help them advance their program forward.” Particle Sciences is a world leader in nano-milling and lipidic formulation technologies, the two most common approaches to difficult toxicological testing challenges. With the ability to manufacture under sterile conditions and to handle highly potent compounds and controlled substances, Particle Sciences delivers solutions to the most complex situations. Particle Sciences’ Chief Executive Officer, Mark Mitchnick, M.D., “No single group has the in-depth expertise in both formulation and toxicology needed to tackle this. Through this combined effort, under a single scope of work, our clients are getting a very valuable service unavailable anywhere else.” Contacts: Anthony Yousefnejad Director, Marketing and Sales Support Calvert Holdings, Inc. Office: +1 919 459 8653 anthony@calvertholdings.com Maureen Mattera Particle Sciences, Inc. Office: +1 610 861 4701 mmattera@particlesciences.com End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|